IL17A and asthma: Blockade of IL-17 using anti–IL-17 antibodies or gene targeting in murine models of asthma reduced mucus hypersecretion, goblet cell hyperplasia, subepithelial collagen deposition, airway smooth muscle thickening, and airway neutrophilia (48–51).